Results 131 to 140 of about 2,453,090 (361)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

SURGICAL OBSERVATIONS IN THE TREATMENT OF THE DISEASES AND ACCIDENTS OF THE LIVER [PDF]

, 1885
Charles K. Briddon
openalex   +1 more source

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review

Frontiers in Pharmacology
BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient.
Yan Wang, Yan Wang, Wenmin Yang, Wenmin Yang, Yuan Yang, Yuan Yang, Xingning Liu, Xingning Liu, Lanfen Peng, Lanfen Peng, Qi Huang, Qi Huang, Qi Huang, Kongli Fan, Kongli Fan, Rui Hu, Rui Hu, Jinyu Yi, Jinyu Yi, Xin Zhong, Xin Zhong, Jing Li, Jialing Sun, Xiaozhou Zhou, Xiaozhou Zhou   +24 more
doaj   +1 more source

Expression and function of osteopontin variants in HCV-related liver disease and hepatocellular carcinoma. [PDF]

, 2010
Osteopontin (OPN) is a highly secreted multi-functional sialoprotein that is widely expressed in tissues, blood and urine. It is involved in a number of normal physiological functions, but is also significantly elevated in a number of cancers.
Phillips, Renee Jade
core   +1 more source

AMMONIUM TOLERANCE IN LIVER DISEASE: OBSERVATIONS BASED ON CATHETERIZATION OF THE HEPATIC VEINS [PDF]

, 1955
Laurens P. White, Elizabeth A. Phear, W.H.J. Summerskill, Sheila Sherlock, M. J. Cole   +4 more
openalex   +1 more source

Thrombocytopenia in Liver Disease [PDF]

Canadian Journal of Gastroenterology and Hepatology, 1999
Moderate thrombocytopenia is a frequent finding in cirrhosis of the liver and well tolerated in most instances. The pathophysiology of thrombocytopenia in liver disease has long been associated with the concept of hypersplenism, where portal hypertension was thought to cause pooling and sequestration of all corpuscular elements of the blood ...
openaire   +4 more sources

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Virology Journal
Purpose The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. Methods
Yisi Liu, Shan Ren, Lina Ma, Xiao Lin, Junfeng Lu, Zhenhuan Cao, Sujun Zheng, Zhongjie Hu, Xiaoxue Xu, Xinyue Chen   +9 more
doaj   +1 more source